About LuminaBio Advisory

Your trusted partner in life sciences consulting.

20+

Years Industry Expertise

Nadya Brady

Life Sciences Consultant with 20+ years’ experience in discovery and clinical drug development across multiple therapeutic areas with a focus on innovative and non-existent solutions for patients. She has led pre-clinical and clinical analytical strategy, drug discovery and clinical development efforts to support therapeutic and preventative development, namely vaccines. She has managed diverse analytical development and matrixed teams at small and large pharma and biotech companies, including Glaxo Smith Kline, GreenLight Bio, Nitto Denko Avecia, and has a broad experience working with collaborators and partners, including CROs and CDMOs. Nadya is passionate about novel therapeutic solutions and medicines that shift standard of care and dramatically improve the lives of patients around the world.

Nadya, during her tenure at GSK, has collaborated with scientific leaders at Novartis and Pfizer to pioneer a New Modalities CMC Network working group as part of the IQ Consortium, a forum for pharmaceutical and biotechnology industry to guide regulatory requirements and accelerate medicine development, which continues to focus on developing controls and regulatory strategies for novel therapeutics, including oligonucleotides, mRNA, ADC, bi-spesific/multispecific antibodies, and radio ligands.